PMID- 16736888
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20131121
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 18
IP  - 2
DP  - 2006 Apr
TI  - Oral etoposide in elderly patients with advanced non small cell lung cancer: a 
      clinical and pharmacological study.
PG  - 188-91
AB  - Seventeen elderly patients with advanced progressive non small cell lung cancer 
      (NSCLC) were treated with oral etoposide at the daily dose of 100 mg for 14 days 
      every 3-4 weeks with pharmacokinetic monitoring. One partial response and 6 
      stabilizations were documented with a median overall duration of 13 weeks (range 
      8-32). The median survival was 24 weeks with an apparent advantage for 
      non-progressive patients (40 weeks vs. 18 weeks). The treatment was well 
      tolerated especially by those patients without concomitant illness, suggesting 
      the crucial role of a careful selection of the geriatric population. Toxicity was 
      not related to the etoposide plasma level, but was clearly dependent on 
      comorbidity. A geriatric assessment rather than chronological age therefore 
      appears to be more reliable in the selection of elderly patients for clinical 
      trials. The easy self-management, favorable toxicity profile and synergy with 
      other compounds makes oral etoposide suitable for further 
      clinical-pharmacological studies in elderly patients.
FAU - Sorio, R
AU  - Sorio R
AD  - Medical Department, Centro di Riferimento Oncologico, Aviano, Italy. 
      rsorio@cro.it
FAU - Toffoli, G
AU  - Toffoli G
FAU - Crivellari, D
AU  - Crivellari D
FAU - Bearz, A
AU  - Bearz A
FAU - Corona, G
AU  - Corona G
FAU - Colussi, A M
AU  - Colussi AM
FAU - Libra, M
AU  - Libra M
FAU - Talamini, R
AU  - Talamini R
FAU - Veronesi, A
AU  - Veronesi A
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 6PLQ3CP4P3 (Etoposide)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Phytogenic/adverse effects/pharmacokinetics/*therapeutic 
      use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Etoposide/adverse effects/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism/secondary
MH  - Male
MH  - Neoplasm Staging
MH  - Survival Rate
EDAT- 2006/06/02 09:00
MHDA- 2006/09/29 09:00
CRDT- 2006/06/02 09:00
PHST- 2006/06/02 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2006/06/02 09:00 [entrez]
AID - 10.1179/joc.2006.18.2.188 [doi]
PST - ppublish
SO  - J Chemother. 2006 Apr;18(2):188-91. doi: 10.1179/joc.2006.18.2.188.